Adjuvant chemoradiation with 5-fluorouracil or capecitabine in patients with gastric cancer after D2 nodal dissection

Anticancer Res. 2012 Apr;32(4):1397-402.

Abstract

Aim: To evaluate outcome and prognostic factors in patients with locally advanced gastric cancer.

Patients and methods: From 2007 to 2011, 55 patients underwent adjuvant radiotherapy and concurrent chemotherapy with 5-fluorouracil (64%) or capecitabine (36%). D2 node resection was performed in all patients. The pathological stage was as follows: 13% IB; 29% II; 24% IIIA; 9% IIIB and 25% stage IV.

Results: The median follow up was 21 months. Five-years overall and disease-free survival were 44.5% and 48%, respectively. Eighteen patients experienced disease relapse after combined treatment; in five of these patients, relapse was both locoregional and systemic. The most common toxicity was grade 1-2 leukopenia, reported in 32% of cases. Six patients developed grade 3 toxicity. Nodal ratio ≥0.4 and N3 stage were significant prognostic factors for survival and relapse.

Conclusion: Adjuvant conformal radiotherapy and concurrent chemotherapy is a feasible and well-tolerated treatment for patients with locally advanced gastric cancer.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Capecitabine
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / therapeutic use
  • Female
  • Fluorouracil / analogs & derivatives*
  • Fluorouracil / therapeutic use*
  • Humans
  • Lymph Node Excision
  • Male
  • Middle Aged
  • Radiotherapy, Adjuvant
  • Stomach Neoplasms / drug therapy
  • Stomach Neoplasms / radiotherapy
  • Stomach Neoplasms / surgery
  • Stomach Neoplasms / therapy*

Substances

  • Antineoplastic Agents
  • Deoxycytidine
  • Capecitabine
  • Fluorouracil